Intercept Pharmaceuticals, Inc.
ICPT
ICPT was delisted on the 7th of November, 2023.
151 hedge funds and large institutions have $568M invested in Intercept Pharmaceuticals, Inc. in 2021 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 42 increasing their positions, 55 reducing their positions, and 39 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
13% less capital invested
Capital invested by funds: $650M → $568M (-$82.5M)
14% less funds holding
Funds holding: 175 → 151 (-24)
22% less call options, than puts
Call options by funds: $24.8M | Put options by funds: $31.9M
24% less repeat investments, than reductions
Existing positions increased: 42 | Existing positions reduced: 55
59% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 39
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
+$17M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$14.2M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$13M |
| 4 |
State Street
Boston,
Massachusetts
|
+$7.93M |
| 5 |
SB
Samsara BioCapital
Palo Alto,
California
|
+$6.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
-$33.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$17.5M |
| 3 |
Goldman Sachs
New York
|
-$14.1M |
| 4 |
Renaissance Technologies
New York
|
-$11.2M |
| 5 |
JP Morgan Chase
New York
|
-$9.84M |
ICPT Hedge Fund Activity: Q1 2021 in Review
151 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Intercept Pharmaceuticals, Inc. (ICPT) for Q1 2021, worth a combined $568M — down 13% from $650M a quarter earlier.
Sellers outnumbered buyers: 39 funds closed out of ICPT and 16 opened new positions — a net loss of 23 holders — while 55 trimmed existing stakes and 42 added.
The largest buyer was First Trust Advisors, adding an estimated $17M. The largest seller was Ameriprise, cutting an estimated $33.1M.
- 151 institutional investors held Intercept Pharmaceuticals, Inc. (ICPT) as of Q1 2021, down from 175 in Q4 2020.
- Funds reported $568M of Intercept Pharmaceuticals, Inc. stock for Q1 2021, down 13% quarter-over-quarter.
- 16 funds opened new Intercept Pharmaceuticals, Inc. positions in Q1 2021 and 39 closed out, a net change of -23 holders.
- The largest Intercept Pharmaceuticals, Inc. buyer in Q1 2021 was First Trust Advisors, an estimated $17M added.
- The largest Intercept Pharmaceuticals, Inc. seller in Q1 2021 was Ameriprise, an estimated $33.1M sold.
Based on aggregated 13F filings for Q1 2021.